



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

FEB 20 2008

Food and Drug Administration
Center for Devices and
Radiological Health
9200 Corporate Blvd
Rockville, MD 20850

Mr. Ammad Nadim
Chief Executive Officer (CEO)
Ammad Surgical
41-B Commercial Area Cavalry Ground
Lahore, Cantt - Pakistan

and

Mr. Shakeel Baig
Managing Partner
International Quality System Consultants
Talwara Mughlan
Sialkot, Pakistan

Dear Messrs. Nadim and Baig:

This is to acknowledge receipt of an October 1, 2007, letter from Mr. Shakeel Baig certifying the compliance of Ammad Surgical with the Food and Drug Administration (FDA) Quality System Regulation of 1997, which includes the current good manufacturing practice (CGMP) requirements. The Quality System Regulation is set forth in Title 21, Code of Federal Regulations (CFR), Part 820. The consultant certification confirmed that a quality system audit of Ammad Surgical was performed September 14, 2007 and a corrective action plan was implemented and verified on September 27, 2007.

The quality system audit report states that Ammad Surgical manufactures surgical instruments. Based on our review of the audit results and certification, Ammad Surgical has been placed on Attachment A of Import Alert #76-01 (Detention without Physical Examination of Surgical Instruments). You may begin exporting devices to the United States (U.S.) that were manufactured after the consultant certified your firm's compliance with the CGMP's; however, your shipments may be subject to the guidance outlined in Attachment A of Import Alert #76-01. After five consecutive shipments comply with the import alert guidance, you may request your firm be placed on Attachment B. Submit your request directly to the FDA district office for their concurrence and further submission to this office for action.

The placement of the firm on Attachment A is limited to devices manufactured under the name of Ammad Surgical, 41-B Commercial Area Cavalry Ground, Lahore, Cantt - Pakistan. In the event the manufacturing name and/or address change, FDA requests that notification be immediately forwarded to this office. A change in the name and/or address of the manufacturing facility without notifying FDA will result in a re-evaluation of the compliance status of your firm.

Messrs Nadim and Baig
Page 2


The decision based on your consultant certification will remain in effect until such time as FDA is able to visit Lahore, Cantt, Pakistan for an inspection of your facility. During this inspection, all corrections and procedures will be evaluated and confirmed. Any new CGMP deviations, or any uncorrected deviations that were previously certified to, may result in a re-evaluation of the compliance status of your firm, Ammad Surgical, including the possibility of removal from Attachment A.

We request that a quality system follow up audit be performed at Ammad Surgical within six months of exporting devices to the U.S. You will be advised of the timing of FDA's inspection schedule.

Ammad Surgical has an ongoing responsibility to conduct internal self-audits to assure you continue to maintain conformance with the Quality System Regulation.

If you have any questions regarding this correspondence, or need further assistance, please contact Brenda Pope at (240) 276-0115 or FAX (240) 276-0114.

Sincerely yours,

A handwritten signature in dark ink, appearing to read "Thomas C. Knott", with a stylized flourish at the end.

Thomas C. Knott
Chief
General Surgery Devices Branch
Division of Enforcement A
Office of Compliance
Center for Devices and
Radiological Health